Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread.
- Your tumor tests positive for two specific proteins: CLDN18.2 (in at least 75% of cells) and PD-L1 (CPS score of 1 or higher).
- You have not had chemotherapy or immunotherapy for advanced cancer, except possibly a short course (up to 2 weeks) of one chemo type.
- You are able to walk and care for yourself (ECOG score 0 or 1), and your doctor believes you will live at least 3 more months.
- You do not have certain other health conditions like active infections, severe heart problems, or untreated ulcers.
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
This early access program offers the investigational drug zolbetuximab for people with advanced stomach cancer that has a specific protein marker. The study aims to make this targeted treatment available before it is fully approved, potentially helping those who have limited options.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
This study tests a new combination treatment for advanced stomach or gastro-esophageal cancer that has not responded to standard treatments. The trial aims to see if the drug combination is safe and effective, potentially offering a new option for people with this type of cancer.
Hear when a new Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.